Visão geral da empresa
A clinical-stage biotechnology enterprise, Equillium, Inc. specializes in the development of therapeutic solutions designed to address severe autoimmune and inflammatory disorders with significant unmet medical needs within the United States market. The company operates within the broader Healthcare sector and specifically functions in the Biotechnology industry, a domain characterized by high R&D expenditure and regulatory hurdles before product commercialization. The enterprise holds a market capitalization of $120.76M, while specific data points for annual revenue and employee count are not disclosed in the available financial records. The market cap figure of $120.76M indicates a mid-cap positioning that reflects investor expectations for potential future commercialization rather than current cash flow generation, given the absence of reported revenue and the company's early-stage development status.
Saúde financeira
The financial statements for Equillium, Inc. report a Net Income (TTM) of $-22,398,000 and an EBITDA of $-23,518,000, with Revenue (TTM) listed as unavailable in the provided data. The substantial negative net income relative to the reported EBITDA suggests a cost structure where non-operating expenses or interest costs significantly impact the bottom line, although the gross margin of 0.0% indicates that revenue figures are either not yet recognized or are insufficient to cover the cost of goods sold in a traditional sense. The company generated Free Cash Flow of $-14,327,250, a metric that signals a consumption of cash reserves typical for clinical-stage entities focused on research and development rather than profit distribution. Regarding liquidity, the firm maintains a Cash balance of $30.28M against a Debt level of $719,000, resulting in a Debt to Equity ratio of 2.51. This high debt-to-equity figure, combined with the negligible debt absolute value, presents a unique leverage profile where the company relies heavily on equity financing but carries minimal interest-bearing obligations. The Current Ratio stands at 10.58, indicating an extremely robust short-term liquidity position where current assets vastly exceed current liabilities, providing ample buffer for operational runway. Return on Equity is reported at -94.0% and Return on Assets at -51.4%, metrics that reflect the dilutive effect of losses on shareholder value and asset utilization typical of pre-revenue biotechnology firms.
Avaliação de valorização
Valuation multiples for Equillium, Inc. present a complex picture due to the company's lack of profitability, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -7.28. The negative forward P/E implies that the market anticipates continued losses or that earnings are projected to remain negative, preventing the use of traditional trailing earnings multiples for valuation comparisons. The Price to Book ratio is 4.11, suggesting that the market values the company's equity at more than four times its book value, a premium that investors assign to the potential of the lead product candidate Itolizumab. Alternative valuation metrics include a Price to Sales ratio of N/A and an EV/EBITDA of -3.88, which further underscores the speculative nature of the investment and the reliance on future commercial success rather than current sales performance. Price metrics show a 52-Week High of $2.70 and a 52-Week Low of $0.27; without a specific current price provided in the facts, the trading range indicates significant volatility within a spread of $2.43. The Beta is 1.74, indicating that the stock's price volatility is 74% higher than the broader market, reflecting the high risk associated with clinical-stage biotechnology assets.
Growth & Income
Equillium, Inc. reports N/A for both Revenue Growth (YoY) and Earnings Growth (YoY), meaning historical growth rates cannot be calculated from the available data to determine if earnings are growing faster or slower than revenue. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. Consequently, the firm does not distribute earnings to shareholders but instead retains all capital to fund its clinical trials and research initiatives. The overall growth and income profile is defined by a complete absence of current profit generation or dividend income, with the entire corporate strategy focused on achieving clinical milestones to eventually generate revenue and shareholder value.